Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators by Lien Thi Ngo, Jaeyeon Lee, Hwi-yeol Yun, Jung-woo Chae

Subjects: Get full text

Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19 by Carsten Schade Larsen

Subjects: Get full text

Identifying key transcription factors and miRNAs coregulatory networks associated with immune infiltrations and drug interactions in idiopathic pulmonary arterial hypertension by Qian Li, Minawaer Hujiaaihemaiti, Jie Wang, Md. Nazim Uddin, Ming-Yuan Li, Alidan Aierken, Yun Wu

“…Also, we employed a molecular docking approach to evaluate the potential protein-drug interactions. Results: We found that 14 TFs encoding genes, including ZNF83, STAT1, NFE2L3, and SMARCA2 are upregulated, and 47 TFs encoding genes, including NCOR2, FOXA2, NFE2, and IRF5 are downregulated in IPAH relative to the control. …”
Get full text

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine by Lien Thi Ngo, Sung‐yoon Yang, Sooyoung Shin, Duc Tuan Cao, Hung Van Nguyen, Sangkeun Jung, Jae‐Young Lee, Jong‐Hwa Lee, Hwi‐yeol Yun, Jung‐woo Chae

“…To illustrate the performance of the developed RIV PBPK model on the prediction of drug–drug interactions (DDIs), carbamazepine (CBZ) was selected as a case study due to the high DDI potential. …”
Get full text

Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters by Aline Barth, Caroline R. Perry, Shaila Shabbir, Maciej J. Zamek‐Gliszczynski, Sebin Thomas, Etienne F. Dumont, Darin B. Brimhall, Dung Nguyen, Meenakshi Srinivasan, Brandon Swift

“…Based on nonclinical in vitro characterization of gepotidacin metabolism, two phase I studies were conducted in healthy participants to investigate clinical drug–drug interactions (DDIs). We assessed gepotidacin as a DDI victim with a potent cytochrome P450 (CYP) 3A4/P‐glycoprotein (P‐gp) inhibitor (itraconazole), potent CYP3A4 inducer (rifampicin), and nonspecific organic cation transporter (OCT)/multidrug and toxic extrusion transporter (MATE) renal transport inhibitor (cimetidine) via single doses of gepotidacin before and after co‐administration with multiple doses of the modulator drugs. …”
Get full text

Drug binding and drug-drug interaction considerations in individuals with obesity before and after bariatric surgery: A retrospective cross-sectional study by Emerita Quintina de Andrade Moura, Carolina Dumke de Siqueira, Ana Carolina Martins, Bruno Fonseca Nunes, Ana Carolina Rabello de Moraes, Fabíola Branco Filippin-Monteiro

“…Before surgery, it was found that more than half of the patients had at least one drug interaction in their therapeutic regimen. Of these, most were classified as moderate. …”
Get full text

COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS by O. V. Zhukova, I. N. Kagramanyan, A. L. Khokhlov

“…The safety of the drug use was assessed by analyzing potential drug interactions. The information about potential drug interactions, was obtained from a specialized website – Drugs.com. …”
Get full text

Application Prospects of FTIR Spectroscopy and CLSM to Monitor the Drugs Interaction with Bacteria Cells Localized in Macrophages for Diagnosis and Treatment Control of Respiratory Diseases by Igor D. Zlotnikov, Alexander A. Ezhov, Maksim A. Vigovskiy, Olga A. Grigorieva, Uliana D. Dyachkova, Natalia G. Belogurova, Elena V. Kudryashova

Get full text

Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform by Cosgrove, P. A., Dunn, R. T., Stolz, D. B., Hamadeh, H., Afshari, C., McBride, H., Long, Thomas J, Griffith, Linda G

Get full text
Get full text

Acute massive pulmonary embolism in a patient using clavis panax by İsa Öner Yüksel, Şakir Arslan, Göksel Çağırcı, Akar Yılmaz

Subjects: “…herb-drug interactions…”
Get full text

Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department by Elena-Codruța Dobrică, Mihnea-Alexandru Găman, Matei-Alexandru Cozma, Ovidiu Gabriel Bratu, Anca Pantea Stoian, Camelia Cristina Diaconu

Subjects: Get full text

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo by Dimitrios Vagiannis, Youssif Budagaga, Anselm Morell, Yu Zhang, Eva Novotná, Adam Skarka, Sarah Kammerer, Jan-Heiner Küpper, Ivo Hanke, Tomáš Rozkoš, Jakub Hofman

Subjects: Get full text

Pharmacokinetic Herb-Drug Interactions of Glipizide with <i>Andrographis paniculata</i> (Burm. f.) and Andrographolide in Normal and Diabetic Rats by Validated HPLC Method by Elza Sundhani, Agung Endro Nugroho, Arief Nurrochmad, Ika Puspitasari, Dita Amalia Prihati, Endang Lukitaningsih

Subjects: “…herb–drug interactions…”
Get full text

Evaluation of pharmacological and pharmacokinetic herb-drug interaction between irinotecan hydrochloride injection and Kangai injection in colorectal tumor-bearing mice and healthy rats by Yanfei Chen, Yanfei Chen, Zhaoliang Hu, Jing Jiang, Chenxi Liu, Shuxiao Gao, Min Song, Taijun Hang

Subjects: “…herb-drug interaction…”
Get full text

Novel Method for Early Prediction of Clinically Significant Drug–Drug Interactions with a Machine Learning Algorithm Based on Risk Matrix Analysis in the NICU by Nadir Yalçın, Merve Kaşıkcı, Hasan Tolga Çelik, Karel Allegaert, Kutay Demirkan, Şule Yiğit, Murat Yurdakök

Subjects: “…drug–drug interactions…”
Get full text

Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics by Camille Lenoir, Amine Niederer, Victoria Rollason, Jules Alexandre Desmeules, Youssef Daali, Caroline Flora Samer

“…Abstract Xenobiotics can interact with cytochromes P450 (CYPs), resulting in drug–drug interactions, but CYPs can also contribute to drug–disease interactions, especially in the case of inflammation, which downregulates CYP activities through pretranscriptional and posttranscriptional mechanisms. …”
Get full text

A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions by Alison Evans, Alison Evans, Debabrata Roy, Debabrata Roy, Sandeep Dhanda, Sandeep Dhanda, Samantha Lane, Samantha Lane, Graça Coutinho, Anuradha Kulasekaran, David Miller-Shakesby, Nagalakshmi Ramamoorthi, Saad Shakir, Saad Shakir

Subjects: Get full text

ABC Transporters and CYP3A4 Mediate Drug Interactions between Enrofloxacin and Salinomycin Leading to Increased Risk of Drug Residues and Resistance by Min Chen, Yujuan Yang, Yupeng Ying, Jiamin Huang, Mengyuan Sun, Mian Hong, Haizhen Wang, Shuyu Xie, Dongmei Chen

Subjects: Get full text

Prediction of the Impact of CYP2C19 Polymorphism on Drug-Drug Interaction between Voriconazole and Tacrolimus Using Physiologically-Based Pharmacokinetic Modelling by Zhi-Ping Jin, Miao Yan, Si-Ze Li, Bao-Qing Wang, Qing Xu, Wei Wu, Xiao-Yu Li, Qian-Zhou Lv, Xiao-Qiang Xiang

Subjects: Get full text

Studies on Chemical Characterization of Ginkgo Amillaria Oral Solution and Its Drug–Drug Interaction With Piceatannol 3′-O-β-D-Glucopyranoside for Injection by Zhenyan Yu, Xiaohan Hu, Lin Zhou, Huliang Chen, Yanchao Xing, Chunyue Han, Hui Ding, Lifeng Han, Guixiang Pan, Zhifei Fu

Subjects: Get full text